Kaletra (Lopinavir 200 mg / Ritonavir 50 mg) – Patient Information (UK)

Kaletra is an antiretroviral medicine used in the treatment of HIV (Human Immunodeficiency Virus). It contains two medicines in one tablet or formulation: lopinavir 200 mg and ritonavir 50 mg. The combination is designed to help control HIV infection by slowing viral replication and supporting consistent drug levels in the body.

This page explains how Kaletra works, how it is usually taken, common safety considerations, and practical guidance for day-to-day use in the United Kingdom.

Basic product information

How Kaletra works (mechanism of action)

HIV needs to produce specific enzymes in order to create new viral particles. One key enzyme is the HIV protease. Lopinavir is a protease inhibitor that blocks HIV protease. This prevents HIV from maturing correctly, which reduces the number of infectious new viruses.

Ritonavir is included at a low dose mainly to boost lopinavir. Ritonavir inhibits enzymes responsible for breaking down lopinavir (particularly CYP3A4), helping lopinavir stay at effective levels for longer.

Pharmacokinetics (how the body handles the medicine)

Pharmacokinetics describes absorption, distribution, metabolism, and elimination.

• Absorption: Lopinavir absorption can be affected by food, and it is typically recommended to take Kaletra with food to improve absorption.
• Distribution: Lopinavir distributes throughout the body; it binds partly to plasma proteins.
• Metabolism: Lopinavir is mainly metabolised in the liver, largely through pathways involving CYP3A. Ritonavir “boosting” helps slow this metabolism.
• Elimination: The drug and its metabolites are eliminated mostly via the biliary/faecal route, with a smaller component in urine.

In practice, the key takeaway is that Kaletra relies on consistent boosting and careful management of other medicines that can change these enzyme pathways.

What Kaletra is used for (typical use)

Kaletra is used as part of combination therapy for people living with HIV. It is designed to reduce viral load and help maintain immune function.

Depending on the individual case, Kaletra may be considered when:

• It is appropriate to use a protease inhibitor–based regimen.
• There is a need to achieve viral suppression using active agents that account for resistance patterns.
• It is suitable based on drug–drug interaction considerations and past treatment history.

Important: HIV treatment regimens are personalised. The best option for one person may not be suitable for another.

How to take Kaletra (timing and dosing approach)

Many people take Kaletra as a twice-daily regimen (every 12 hours). However, dosing schedules can vary based on formulation and clinical circumstances.

General timing guidance

• Try to take each dose at consistent times each day.
• Take with food when possible to improve absorption and tolerability (follow local product guidance and prescriber instructions).
• If you miss a dose, follow the advice provided for your regimen (for example, take it when remembered unless it is close to the next dose; do not double up).

Typical dosing

The exact dose depends on the prescribed regimen and whether you use tablets or oral liquid.

Because dosing can vary, this page provides general guidance rather than a “one-size-fits-all” prescription dose:

• Adults (common approach): often twice daily dosing in a protease inhibitor–based regimen.
• Children: dosing may be weight-based and differs from adult dosing; oral liquid is often used.
• Renal impairment: usually no major adjustment is required, but monitoring is advised.
• Liver impairment: may affect metabolism; clinicians may adjust or monitor closely.

Always follow the instructions on your medicine label and any accompanying patient information leaflet for your specific formulation.

Food interactions

Taking Kaletra with food is commonly advised because it can improve absorption. Food does not eliminate the need for correct timing and dose consistency.

Practical eating tips

• Try to take doses with meals or a substantial snack, especially at the start of therapy.
• If you have a sensitive stomach, taking with food can help reduce nausea.
• Do not rely on antacids or buffered medicines to “fix” absorption—discuss timing with your clinician/pharmacist.

Alcohol and medicine interactions

Alcohol does not have the same direct “contraindication” profile for Kaletra as with some other antiretrovirals, but caution is still important.

• Liver health: Both HIV itself and antiretroviral medications can affect the liver. Alcohol may add extra strain, especially if you already have liver disease (e.g., hepatitis B or C).
• Side effects: Alcohol can worsen symptoms such as nausea, dizziness, fatigue, or headaches.
• Medication adherence: Alcohol can contribute to missed doses. Consistency is crucial for controlling HIV.

Advice: If you drink alcohol, consider keeping it moderate and discuss safe limits with a healthcare professional—especially if you have any liver conditions or raised liver enzymes.

Medicine interactions (very important)

Kaletra has major drug–drug interaction potential because ritonavir significantly affects liver enzymes (notably CYP3A) and drug transport mechanisms.

Examples of medicines that may interact

Some medicines can:

• Lower Kaletra levels (making it less effective)
• Increase Kaletra levels (raising the risk of side effects)
• Create potentially serious effects when combined

Important: The list of interactions is broad. Always check with your pharmacist or clinician before starting, stopping, or changing any medicine, including over-the-counter products.

Some commonly discussed categories include:

• Antacids or ulcer medicines (timing may matter)
• Anticoagulants (blood thinners)
• Statins (cholesterol medicines)
• Antiarrhythmics (heart rhythm medicines)
• Anti-seizure medicines (can change metabolism)
• Rifamycin antibiotics used for certain infections
• Herbal preparations (especially St John’s wort)

Food/supplement interactions

• Herbal products: Some can reduce antiretroviral effectiveness or increase side effects.
• Grapefruit products: may affect metabolism of many medicines and can change drug exposure; it’s often advised to avoid or seek advice.

What to do

• Keep an up-to-date list of all medicines and supplements.
• Check every new medicine for interactions.
• If you receive another prescriber’s medication, ensure your HIV team/pharmacist is informed.

Indications (when Kaletra may be prescribed)

Kaletra is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. Use is guided by:

• History of previous antiretroviral treatment
• Virological response (e.g., viral load)
• Resistance test results, when available
• Potential interactions with current medications
• Safety considerations and laboratory monitoring needs

In the UK, treatment is coordinated through specialist HIV services and aligned with current national/international guidance.

Safety profile and side effects

Like all medicines, Kaletra can cause side effects. Not everyone will experience them, and severity varies between individuals.

Common side effects

• Diarrhoea
• Nausea, indigestion, abdominal discomfort
• Headache
• Fatigue
• Changes in cholesterol and triglycerides
• Sometimes rashes

Serious side effects (seek medical help promptly)

• Signs of liver problems: yellowing of the skin/eyes (jaundice), dark urine, severe tiredness, pain in the upper right abdomen
• Severe allergic reactions: swelling of the face/lips, difficulty breathing
• Unusual bleeding or bruising if you are taking blood thinners with interacting medicines
• Severe abdominal pain or persistent vomiting (possible pancreatitis, though uncommon)
• Muscle pain/weakness with certain interacting medicines (for example, some statins)

Monitoring while taking Kaletra

Clinicians commonly monitor:

• Viral load and CD4 count
• Liver function tests
• Fasting lipid profile (cholesterol/triglycerides)
• General blood count and other safety parameters as appropriate

Note: Tell your healthcare team if you develop symptoms or if other medicines are added or changed.

Practical use tips (getting the best results)

• Build routine: Choose times that match meals (e.g., breakfast and dinner) and set reminders.
• Do not stop or miss doses: Maintaining consistent drug levels helps prevent viral rebound and resistance.
• Handle missed doses carefully: Follow leaflet/regimen instructions. If unsure, contact a pharmacist or HIV clinic.
• Watch for diarrhoea: Stay hydrated and report persistent diarrhoea to your clinician, as it can affect nutrition and adherence.
• Medication list discipline: Carry a list of your medicines and allergies.
• Attend monitoring appointments: Lipids and liver tests are important for long-term safety.
• Prevent interaction surprises: Always check before using new OTC products (including cough/cold remedies) and supplements.

Alternative options

There are several classes of antiretroviral medicines. Alternatives to Kaletra depend on individual factors such as resistance, treatment history, co-morbidities, and interaction profile.

Common alternative categories (examples)

• Integrase strand transfer inhibitors (INSTIs) (often used in first-line regimens due to convenience and strong efficacy)
• Other protease inhibitors (sometimes used with different boosting strategies)
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
• Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as backbone components in combination regimens

Your HIV specialist will recommend the most suitable regimen. If switching is considered, it should be done under clinical supervision to maintain viral suppression safely.

UK market and legal context (pharmacy and supply)

In the United Kingdom, HIV antiretroviral medicines are regulated and supplied through established healthcare pathways. Availability may vary by formulation (tablets vs oral liquid) and stock status. Pharmacies typically follow UK medicines legislation and quality controls, including:

• Product licensing and authorisation by UK regulatory bodies
• Pharmacovigilance reporting for safety concerns
• Pharmacy compliance with dispensing and controlled processes where applicable

People in the UK are supported by specialist HIV services and national guidance (e.g., clinical commissioning approaches and evidence-based recommendations). Prescribing decisions also consider local formularies and availability.

Recent guidance and clinical context (UK)

HIV treatment guidance in the UK is regularly updated to reflect evolving evidence, safety considerations, and best practice. In recent years, many clinicians have favoured regimens that are:

• Highly effective for viral suppression
• Well tolerated long term
• Convenient (often once-daily options when appropriate)
Low interaction risk when possible

That said, protease inhibitor–based therapy including boosted regimens like Kaletra may remain important for certain patients. The choice depends on individual factors such as prior resistance and interaction needs.

Always rely on current advice from your HIV care team, as recommendations may change.

Delivery and availability (UK online pharmacy)

Availability of Kaletra can depend on:

• The exact formulation needed (tablets or oral liquid)
• Strengths and pack sizes
• Regional distribution and stock rotation
• Seasonal demand and supply chain conditions

When ordering online, typical delivery expectations in the UK may include standard and express options depending on provider services. Many pharmacies also offer:

• Discreet packaging
• Tracking where available
• Substitution policies only if allowed and appropriate (always confirmed before dispatch)

Tip: If you are close to running out, choose a delivery option that provides sufficient time and consider allowing for potential delays.

FAQ

1) What is Kaletra used for?

Kaletra is used in the treatment of HIV-1 infection. It is taken as part of combination antiretroviral therapy to reduce viral load and support immune function.

2) How should I take Kaletra?

Many people take Kaletra twice daily and it is generally recommended to take it with food to improve absorption. Always follow your specific regimen instructions.

3) Can I take Kaletra with or without food?

Food is commonly recommended because it can improve drug absorption and tolerability. If your regimen instructions say to take with food, aim to follow that closely.

4) What if I miss a dose?

Missed-dose advice depends on your schedule. In general, don’t double up. If you are unsure, ask a pharmacist or contact your HIV clinic for guidance specific to your dosing pattern.

5) What are common side effects?

Common effects include diarrhoea, nausea, abdominal discomfort, headache, and possible changes to cholesterol/triglycerides. Report persistent or severe symptoms to your healthcare team.

6) Are there any serious risks?

Serious risks can include liver problems and pancreatitis (uncommon). Seek urgent medical advice if you develop jaundice, severe abdominal pain, or symptoms of an allergic reaction.

7) Why are drug interactions so important with Kaletra?

Ritonavir strongly affects enzymes that process many medicines. This can either reduce Kaletra effectiveness or increase the risk of side effects from other drugs.

8) Can I drink alcohol while taking Kaletra?

Moderation is advisable, especially if you have liver disease or raised liver enzymes. Alcohol can worsen side effects and adherence. Discuss safe limits with a healthcare professional.

9) What monitoring might I need?

Your clinician may monitor viral load, CD4 count, liver function tests, and blood fats (cholesterol/triglycerides), among other parameters.

10) What are some alternatives to Kaletra?

Alternatives depend on your treatment history and resistance profile. Your specialist may recommend other antiretroviral classes such as INSTIs, other protease inhibitors, NNRTIs, and/or different combinations.

11) Does availability vary in the UK?

Yes. Stock can vary by formulation (tablets vs oral liquid) and pack size. Ordering early and choosing a reliable delivery option can help reduce the risk of running out.

Disclaimer: This information is intended to support understanding and safe use. It does not replace guidance from your healthcare team or the official patient information leaflet provided with your medicine.